In addition, we found that EP300 inhibition by A485 significantly blocked the tumor growth in both VGLL2-NCOA2 and TEAD1-NCOA2 allograft tumor models (Figure 6C and D), and A485 treatment markedly decreased the proliferation of tumor cells (Figure 6E and F) and the transcription of the target genes, including Ccn1, Ccn2, and Ankrd1 (Figure 6G and H), in both VGLL2-NCOA2 and TEAD1-NCOA2 tumor models. The gene discussed is EP300; the disease is neoplasm.